Bottom left-hand image reprinted from Dermatologic Clinics, Vol 29/No. 3, Schmidt E, et al, Clinical features and practical diagnosis of bullous pemphigoid, pp427-438, Copyright 2011, with permission Elsevier. Far bottom-right image reprinted from DermNet New Zealand. Original image located at: <a href="https://dermnetnz.org/topics/bullous-pemphigoid-images" target="_blank">https://dermnetnz.org/topics/bullous-pemphigoid-images.</a> Far top-right image reprinted with permission from Science Photo Library. Original image located at: <a href="https://www.sciencephoto.com/media/1227663/view" target="_blank">https://www.sciencephoto.com/media/1227663/view</a>

Left image reprinted from DermNet New Zealand. Original image located at: <a href="https://dermnetnz.org/topics/bullous-pemphigoid-images" target="_blank">https://dermnetnz.org/topics/bullous-pemphigoid-images</a>

*May persist for several weeks or months before the formation of bullae, or it may remain non-bullous indefinitely in atypical variants.&nbsp;&nbsp;
 
 BP, bullous pemphigoid; QoL, quality of life.

References

BULLOUS-PEMPHIGOID

DERMATOLOGY

Bullous Pemphigoid Burden of Disease and Diagnosis

<h2>Long acting Monoclonal Antibody is now mandatory for all infants in UAE1</h2>

<h2>Abu Dhabi Public Health Centre added RSV-mABs to the Immunization Program2</h2>

Inclusion in Immunization Program:&nbsp;
<ul>
 <li>One dose of L-mAbs for RSV prevention is indicated for infants born during the RSV season (Sept 1 - March 1) in the following cases: &nbsp;&nbsp;&nbsp;
 <ul>
 <li>If the mother did not receive the RSV vaccine &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
 <li>If the infant was born within 14 days of maternal RSV vaccination &nbsp;&nbsp;&nbsp;&nbsp;</li>
 <li>If the maternal RSV vaccination status during pregnancy is unknown &nbsp;&nbsp;</li>
 </ul></li>
</ul>
High-Risk Children: Only Nirsevimab will be administered in the second RSV season to high-risk children aged 8 to 19 months.

<h2>Dubai Health Authority Added RSV-mABs to the Immunization Program3</h2>

<ul>
 <li>A single dose of the Long-acting RSV monoclonal antibodies is administered to newborns at birth who are born between September 1 of one calendar year and March 1 of subsequent year (RSV season), unless the mother received the RSV vaccine during that pregnancy</li>
 <li>Nirsevimab is recommended for some children &lt;19 months who are at increased risk for severe RSV disease and entering their RSV season (1st September to 1st March).
 <ul>
 <li>Children with chronic lung disease of prematurity who required medical support (any time during the 6-month period before the start of the RSV season)</li>
 <li>Children with severe immunocompromise.</li>
 </ul></li>
</ul>

Long acting Monoclonal Antibody is now mandatory for all infants in UAE

RSV Prevention Guidelines in UAE

VACCINES

RESPIRATORY-SYNCYTIAL-VIRUS

Discover a simple way to monitor MS using Acknowledge, Assess, and Advocate—helping you track changes and improve patient conversations.

SPECIALTY-CARE

NEUROLOGY

MULTIPLE-SCLEROSIS

MS pulse Reels - How to Track MS | Acknowledge, Assess, Advocate

Discover a simple way to monitor MS using Acknowledge, Assess, and Advocate—helping you track changes and improve patient conversations.

Access all the content and events you need to continue growing as a health professional.

Welcome To Campus Sanofi UAE

OUT-OF-TAXONOMY

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip) Injection, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Welcome To Campus Sanofi UAE

Scientific News

Bullous Pemphigoid Burden of Disease and Diagnosis

RSV Prevention Guidelines in UAE

MS pulse Reels - How to Track MS | Acknowledge, Assess, Advocate

Quick Links

Support for your patients

Payor